Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.

Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, Aberg JA; AIDS Clinical Trials Group A5108 Team.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):307-12.

PMID:
15980690
2.

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.

Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM.

Antimicrob Agents Chemother. 2001 Dec;45(12):3445-50.

4.

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.

Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P.

Clin Pharmacol Ther. 2000 Oct;68(4):391-400.

PMID:
11061579
5.

Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.

Hulskotte EG, Feng HP, Xuan F, Gupta S, van Zutven MG, O'Mara E, Wagner JA, Butterton JR.

Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8. doi: 10.1128/AAC.02347-12. Epub 2013 Mar 25.

6.

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F; NIAID AIDS Clinical Trials Group.

AIDS. 2002 Mar 8;16(4):569-77.

PMID:
11873000
7.

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

Jones P, Kafonek S, Laurora I, Hunninghake D.

Am J Cardiol. 1998 Mar 1;81(5):582-7. Erratum in: Am J Cardiol 1998 Jul 1;82(1):128.

PMID:
9514454
8.

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group.

Am J Cardiol. 2003 Jul 15;92(2):152-60.

PMID:
12860216
9.

Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.

Hoch M, Hoever P, Theodor R, Dingemanse J.

Eur J Clin Pharmacol. 2013 Jun;69(6):1235-45. doi: 10.1007/s00228-012-1470-8. Epub 2013 Jan 20.

PMID:
23334403
10.

Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.

Hilleman DE, Wurdeman RL, Lenz TL.

Pharmacotherapy. 2001 Apr;21(4):410-5.

PMID:
11310513
11.

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.

Clin Ther. 2004 Sep;26(9):1388-99. Erratum in: Clin Ther. 2005 Jan;27(1):142.

PMID:
15531001
12.

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.

Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S.

Clin Ther. 2008 Jul;30(7):1345-57.

PMID:
18691996
14.

Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.

Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C.

J Clin Pharmacol. 2002 Feb;42(2):222-8.

PMID:
11831546
15.

Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.

Kokudai M, Inui N, Takeuchi K, Sakaeda T, Kagawa Y, Watanabe H.

J Clin Pharmacol. 2009 May;49(5):568-73. doi: 10.1177/0091270009332435.

PMID:
19398603
16.

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

Neuvonen PJ, Kantola T, Kivistö KT.

Clin Pharmacol Ther. 1998 Mar;63(3):332-41.

PMID:
9542477
17.

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.

Lilja JJ, Kivistö KT, Neuvonen PJ.

Clin Pharmacol Ther. 1999 Aug;66(2):118-27.

PMID:
10460065
18.

Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.

Teng R, Mitchell PD, Butler KA.

Eur J Clin Pharmacol. 2013 Mar;69(3):477-87. doi: 10.1007/s00228-012-1369-4. Epub 2012 Aug 25.

PMID:
22922682
19.

A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.

Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R.

J Clin Pharm Ther. 2005 Feb;30(1):21-37.

PMID:
15659001
20.

Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.

Dingemanse J, Nicolas LB, van Bortel L.

Eur J Clin Pharmacol. 2014 Jun;70(6):675-84. doi: 10.1007/s00228-014-1674-1. Epub 2014 Apr 15.

PMID:
24728182

Supplemental Content

Support Center